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One Sentence Summary: A new chemical strategy to correct nuclear architecture defects and 
improve fitness of laminopathic human cells.  
 
 2 
Abstract: Downregulation and mutations of the nuclear-architecture proteins Lamin A and C 
cause misshapen nuclei and altered chromatin organization associated with cancer and 
laminopathies, including the premature-aging disease Hutchinson-Gilford progeria syndrome 
(HGPS). Here, we identified the small molecule “Remodelin” that improved nuclear architecture, 
chromatin organization and fitness of both human Lamin A/C depleted cells and HGPS-derived 
patient cells, and decreased markers of DNA damage in these cells. Using a combination of 
chemical, cellular and genetic approaches, we identified the acetyl-transferase protein NAT10 as 
the target of Remodelin that mediated nuclear shape rescue in laminopathic cells via microtubule 
reorganization. These findings provide insights into how NAT10 affects nuclear architecture, and 
suggest alternative strategies for treating laminopathies and aging. 
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Main Text:  
Mutations in LMNA, which encodes Lamin A and C, cause pathologies known as laminopathies 
(1), including the accelerated-aging disease Hutchinson-Gilford progeria syndrome (HGPS) (2, 3). 
Deregulation of A-type lamins expression or localization also occurs in various cancers (4-6). 
Lamin A/C depletion or LMNA mutations cause enlarged, misshapen nuclei and altered chromatin 
organization (7). While some of these pathologies might reflect cell fragility, many likely result 
from downstream effects on chromatin structure, gene expression, DNA replication or DNA repair. 
Improving nuclear architecture of laminopathic cells can ameliorate defects in chromatin structure 
and other processes, thus improving some disease phenotypes (8, 9). 
 
Lamin A/C depletion by small interfering RNA (siRNA) transfection (siLMNA) caused nuclear-
shape defects (Fig. 1A, B, S1A, B), global chromatin relaxation and increased nuclear area (Fig. 
S1C, D). We therefore reasoned that modulating chromatin organization by lysine 
acetyltransferase (KAT) or lysine deacetylase (KDAC) inhibition might improve nuclear 
architecture defects of siLMNA cells. Compound screening identified the KAT inhibitor 4-(4-
chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)thiazole (1) (Fig. 1C) that restored nuclear 
circularity and global chromatin compaction in siLMNA cells (Fig. 1D, E, S1E-G). Although 
molecule 1 was identified in Saccharomyces cerevisiae as a GCN5 (General control of amino acid 
synthesis protein 5-like 2) network inhibitor (10), nuclear shape rescue was GCN5 independent, 
because the benchmark GCN5 inhibitor MB-3 had no effect on nuclear circularity. Complete 
nuclear-shape rescue occurred within 12 hours of treatment (Fig. 1F), independently of mitosis 
(Fig. S2A and Movie S1) and without markedly affecting the cell cycle (Fig. S2B, C). Moreover, 
compound 1 improved the nuclear morphology of several cancer cell lines displaying reduced 
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Lamin A/C expression (Fig. S2D, E), indicating that its effects were not specific to siRNA-
mediated Lamin A/C depletion.  
 
To identify putative targets of 1, we synthesized a “clickable” cell-active analog 2 and used 
inactive molecule 3 as a negative control (Fig. 1G, H). We then employed “click-chemistry” to 
retrieve and validate drug-associated proteins. The alkyne “click” moiety selectively reacts with 
an azide group upon copper exposure, allowing tagging of the “clickable” molecules in cells (Fig. 
1I). First, we used a biotinylated derivative of 2 (Fig. S3A), retrieved associated proteins with 
streptavidin beads, and identified several protein species whose staining intensities were reduced 
by an excess of competitor 1 (Fig. S2B). These proteins were then identified by mass spectrometry 
LC-MS/MS (Fig. S2C). N-acetyltransferase 10 (NAT10) was the only KAT protein identified, 
thus being the only likely relevant target of 1. NAT10 was previously linked with the SUN1 
nuclear envelope protein (11), whose depletion rescues nuclear shape in LMNA KO cells (8), and 
NAT10 KAT activity has been demonstrated towards microtubules and histones (12). 
 
Pre-incubating clickable molecules with live cells followed by click pull-down identified NAT10 
as a specific target of 2 in vivo (Fig. 1J), thereby establishing our protocol as a framework for 
identifying specific partners without photo-crosslinking agents (13). In parallel, we visualized sub-
cellular localizations of clickable molecules by fluorescence microscopy (14) (Fig. 1K). This 
revealed that 2 specifically accumulated in nucleoli and also localized at the nuclear periphery and 
in the cytoplasm (Fig. 1K and Fig. S4A). Corroborating the binding studies, this distribution 
overlapped with that of NAT10, and moreover, NAT10 depletion (Fig. S4B) led to a marked 
reduction of molecule 2 in the nucleolus (Fig. 1K) without changes in nucleolar architecture (Fig. 
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S4C reveals that NAT10 localization was not affected by treatment with 1 or siLMNA). 
Furthermore, we established direct physical interaction between 1 and NAT10 using circular 
dichroism spectroscopy (Fig. S4D). Because molecule 1 was rapidly degraded upon light or air 
exposure, we explored its structural derivatives for their ability to rescue nuclear shape of siLMNA 
cells (Fig. S5A). The most potent and stable analog identified (4; Fig. S5B) was named 
“Remodelin” based on its ability to remodel nuclear architecture of siLMNA cells (Fig. 1L). 
 
Consistent with a model in which Remodelin impacts on siLMNA cells through NAT10 targeting, 
we found that NAT10 depletion (Fig. 2A) corrected the aberrant nuclear morphology of siLMNA 
cells (Fig. 2B). Because 1, the analog of Remodelin, is a KAT inhibitor, we assessed whether 
Remodelin affected NAT10 KAT activity. Aligning human NAT10 with the 3D structure of its 
bacterial homolog in complex with acetyl-CoA (15) led us to mutate conserved glycine-641 to 
glutamate (G641E), predicted to impair acetyl-CoA binding (Fig. 2C, D, S6A). Indeed, this 
mutation blocked NAT10 activity (Fig. 2E, S6B). Moreover, wild-type NAT10 activity was 
inhibited by Remodelin or clickable molecule 2, establishing Remodelin as a bona fide NAT10 
inhibitor. Complementation assays with siRNA-resistant wild-type (NAT10 WT) or G641E 
mutant NAT10 (NAT10 MUT) (Fig. S6C, D) showed that rescue of nuclear circularity in siLMNA 
cells required NAT10 catalytic function (Fig. 2F). Thus, inactivating NAT10 KAT activity by 
mutation or by Remodelin restores normal nuclear morphology in siLMNA cells. 
 
We next investigated the effects of Remodelin on cells derived from LMNA-mutated HGPS 
patients (AG11498 and AG06297). HGPS cells accumulate Progerin, a permanently farnesylated, 
truncated form of Lamin A, leading to nuclear membrane folding and nuclear blebbing (Fig. 3A) 
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that contribute to the premature-aging phenotypes of HGPS patients. Remodelin significantly 
reduced the prevalence of misshapen nuclei in HGPS cells (Fig. 3B) as well as in primary MRC5 
fibroblasts aged in culture (Fig. S7A, B), which also accumulate Progerin upon extended passaging 
(16). By contrast, Remodelin had no effect on non-laminopathic Werner syndrome cells (Fig. S7C, 
D). Farnesyltransferase inhibitors (FTIs) prevent accumulation of farnesylated Progerin at the 
nuclear membrane, thus reducing HGPS nuclear blebbing (17). Unlike FTIs, however, Remodelin 
did not trigger pre-Lamin A accumulation (Fig. S8A), indicating that Remodelin is not an FTI. 
Remodelin and FTI did not act synergistically on nuclear shape improvement, however, suggesting 
that they impact on a common pathway (Fig. S8B, C).  Unlike Remodelin, FTI did not improve 
nuclear morphology in siLMNA cells. Furthermore, although FTI improves HGPS nuclear shape, 
it had the opposite effect on Progerin-negative cells, (Fig S8B, C) probably by causing 
accumulation of unprocessed Lamin A and B and centrosome separation defects (18-20). By 
contrast, Remodelin prevented FTI-induced nuclear shape defects in normal fibroblasts and U2OS 
cells (Fig. S8B-D). The proportion of misshapen nuclei in HGPS cells was similarly decreased by 
Remodelin treatment or NAT10 depletion (Fig. 3C and Fig. S9A), implying that NAT10 inhibition 
by Remodelin mediates nuclear shape normalization in HGPS cells. 
 
While nuclear shape improvement is not always associated with overall amelioration of HGPS cell 
phenotypes (21), Remodelin improved global HGPS-cell fitness as observed by decreased steady-
state levels of the DNA double-strand break markers γH2AX and autophosphorylated ATM, 
decreased DNA damage signaling (Fig. 3D, S9B-D), improved chromatin and nucleolar 
organization (assessed by histone H3K9me3 and NAT10 staining), and decreased SUN1 
accumulation at the nuclear envelope (Fig. S9E-G). Blocking DNA damage signaling by inhibiting 
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the apical DNA-damage response kinases ATM and ATR decreased γH2AX (Fig. 3E, F). 
However, unlike Remodelin – which improved DNA replication (Fig. S9H), enhanced cell 
proliferation capacity (Fig. 3G) and decreased senescence (Fig. 3H; note other KAT inhibitors did 
not decrease senescence, Fig. S9I) – inhibiting ATM and ATR decreased proliferation and induced 
senescence (Fig. 3G, H). Similar effects were observed upon p53-pathway inhibition (Fig. S9I).  
Thus, Remodelin appears to reduce the amount of DNA damage in HGPS cells, while damage is 
still present but no longer signaled properly upon ATM/ATR inhibition, leading to cell growth 
arrest and senescence. Moreover, Remodelin conferred long-term benefits to HGPS cells, as seen 
by it decreasing senescence even after several weeks of treatment (Fig. 3I).  
  
NAT10 localizes mainly in the nucleolus, which has a known role in maintaining nuclear shape 
(22, 23). For example, depleting the nucleolar protein NPM1 changes microtubule stability (24) 
and affects nuclear shape via connections between the cytoskeleton and nuclear envelope. Because 
tubulin is a known NAT10 substrate, we examined the microtubule network and observed network 
reorganization upon Remodelin treatment, NAT10 depletion, or mutational inactivation of NAT10 
(Fig. 4A). In accord with there being a functional link between microtubule reorganization and 
nuclear shape rescue by NAT10 inhibition, the microtubule destabilizing drugs nocodazole and 
colchicine also rescued the nuclear shape defects of siLMNA cells (Fig. 4B) and HGPS cells (Fig. 
S10A), while latrunculin A, an actin polymerization inhibitor, increased nuclear distortion. 
Remodelin effects were not linked to Golgi apparatus fragmentation or tubulin depolymerization 
because, in contrast to nocodazole or colchicine, Remodelin did not affect Golgi apparatus 
integrity or tubulin polymer assembly (Fig. 4C and D), and did not cause cells to accumulate in 
mitosis.  
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To gain insight into how NAT10 modifies microtubule organization, we analysed microtubule 
regrowth dynamics. While initial microtubule regrowth (nucleation phase) appeared normal after 
NAT10 inhibition in siLMNA cells (Fig. 4E t=5 min) and HGPS cells (Fig. S10C), microtubule 
anchorage to centrosomes was affected by Remodelin in both siLMNA cells (Fig. 4E) and HGPS 
cells (Fig. S10B), or by the NAT10 G641E mutation (Fig. 4E t=15 min), indicating that NAT10 
KAT activity promotes microtubule anchorage. These results suggest that inhibiting NAT10 KAT 
activity in laminopathic cells reduces microtubule anchorage, thereby releasing an external force 
on the nuclear envelope, thus contributing to nuclear shape rescue and global enhancement of 
cellular fitness (Fig. S11). This is in line with studies showing that releasing microtubule forces 
on the nucleus by growing them on a “soft” substrate normalizes the nuclear shape of laminopathic 
cells (25), and helps explain why Remodelin, like other microtubule reorganizing agents (26), 
corrects FTI-induced nuclear shape defects in non-progeric cells (Fig. S8).  
 
Here, we have shown that the small molecule Remodelin improves nuclear shape and fitness of 
both progeric and Lamin A/C depleted cells via inhibiting NAT10. While these effects appear to 
be connected to NAT10 organizing the microtubule network, we cannot rule out that inhibiting 
additional nuclear functions of NAT10, related to chromatin, might also contribute to global 
improvement of cellular fitness. Small molecule inhibitors of NAT10 may thus provide additional 
ways to study laminopathy-associated processes with spatial and temporal resolution, as well as 
opportunities for alleviating dystrophic and premature-ageing diseases.  
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Figures 
 
Figure 1: A small molecule restores nuclear shape in Lamin A/C depleted cells and targets 
the acetyltransferase NAT10.  A) Lamin A/C depletion (siLMNA) in U2OS cells compared to 
negative control (siCT). B) Nuclear shape observed by DAPI staining. C) Molecular structure of 
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4-(4-chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)thiazole (1).  D) Nuclear shape rescue 
observed by DAPI staining after treatment with 1. E) Quantification of nuclear circularity in non-
treated (NT) cells or cells treated with the indicated compounds (means of three independent 
experiments with n>212  s.d.). F) Live imaging pictures of nuclear shape rescue in GFP-H2B 
expressing U2OS cells transfected with siLMNA and treated with 1. G) Molecular structure of 
clickable analogue 2 and clickable inactive control molecule 3. H) Quantification of U2OS nuclear 
circularity (means of three independent experiments with n>224  s.d.) I) Principle of click-
chemistry strategy for small molecule tagging. J) Pull-down of clickable molecules 2 and 3 pre-
incubated in U2OS cells and analysis of bound proteins. K) Representative high-resolution 
microscopy pictures of NAT10 (red) and fluorescently labeled 2 (green) in control or NAT10 
depleted cells (siNAT10). Scale bars: 10 µm. L) Molecular structure of Remodelin (4), a stable 
and more potent analog of 1.  
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Figure 2: Inhibiting NAT10 activity by Remodelin mediates nuclear shape rescue of LMNA 
depleted cells. A) NAT10 and Lamin A/C depletion in U2OS cells. B) Nuclear shape visualized 
by DAPI staining (left) and quantification of nuclear circularity (right; means of three independent 
experiments with n>267  s.d.). Scale bar: 20 µm. C) Representation of NAT10 with its known 
domains. The G641E mutation identified in D) is indicated in dark blue and asterisked. D) 
Modelled 3D structure of human NAT10 residues 10-917 showing the acetyl-CoA binding site 
(left) and disruption of Ac-CoA binding by NAT10 G641E mutation (right) visualized with Swiss-
Prot PDB Viewer. E) In vitro acetylation assay showing the activity of NAT10 towards tubulin. F) 
Quantification of nuclear circularity (left) in cells stably expressing siRNA-resistant FLAG-
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NAT10 WT or FLAG-NAT10 G641E (NAT10 MUT; means of three independent experiments 
with n>198  s.d.) and nuclear shape visualized by DAPI staining (right). Scale bar: 20 µm. 
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Figure 3: Remodelin targets NAT10 to improve nuclear shape and fitness of HGPS cells. A) 
Representative immunofluorescence (IF) pictures of Lamin A/C in HGPS cell lines compared to 
matched normal fibroblasts at the same population doubling. Scale bar: 10 µm. B) Quantification 
of misshapen nuclei upon Remodelin treatment (means of three independent experiments with 
n>213  s.e.m.). C) Lamin A/C staining in HGPS AG11498 cells (left) and quantification of 
misshapen nuclei (right; means of three independent experiments with n>176  s.e.m.). Scale bar: 
50 µm. D) Western blotting analysis of γH2AX after Remodelin or FTI treatment. E) 
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Immunofluorescence analysis of γH2AX staining upon Remodelin or ATM/ATR inhibition 
(ATM/ATRi).  F) Quantification of γH2AX positive cells observed by IF (means of three 
independent experiments with n>127  s.e.m.). G) HGPS proliferation upon Remodelin or 
ATM/ATR-inhibitor treatment (means of nine replicates  s.e.m). H) Quantification of 
senescence-associated b-galactosidase positive cells (means of three independent experiments 
with n>257  s.e.m.). I) Quantification of senescence-associated b-galactosidase positive cells in 
HGPS AG11498 after 8 days of Remodelin treatment at population doubling 12 (PDL 12) and 
after several weeks of Remodelin treatment and 12 cell divisions (PDL 24) (means of two 
independent experiments with n>298  s.d.).  
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Figure 4: Inhibiting NAT10 acetyltransferase activity modifies microtubule organisation to 
rescue nuclear shape defects. A) Microtubule network visualisation by inverted IF pictures of α-
tubulin. B) Nuclear shape visualisation after treating cells with microtubule or actin cytoskeleton 
disrupting agents. C) Visualisation of nuclear shape (DAPI, blue) and Golgi (anti-Giantin, green) 
integrity in siLMNA cells. D) Fractionation of polymerized (P) and soluble (S) tubulin upon 
Remodelin or nocodazole (Nocod.) treatment. E) Microtubule regrowth in cells transfected with 
siNAT10 and expressing the indicated siRNA-resistant constructs. α-tubulin IF staining (left) 
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shows nucleation phase: t=5 min and microtubule anchorage (t=15 min). Right: quantification of 
cells with indicated patterns (means of three independent experiments with n>103  s.e.m.). 
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Materials and Methods 
Cell culture and transfections. U2OS and SaOS-2 osteosarcoma cells, HeLa cervical 
cancer cells, A431 melanoma cells, NCI-SNU5 gastric cancer cells, MRC-5 lung 
fibroblast cells and Werner syndrome patient-derived SV40 fibroblast cells were grown 
in Dulbecco’s modified Eagle medium (DMEM, Sigma-Aldrich) supplemented with 10% 
fetal bovine serum (BioSera), 2mM L-glutamine, 100U per ml penicillin, 100 µg ml-1 
streptomycin. Normal skin primary fibroblasts GM03440 and Hutchinson-Gilford 
progeria syndrome (HGPS) skin primary fibroblasts AG11498 and AG06297 were 
purchased from Coriell Cell Repositories and used between passage number 9-25. Cells 
were grown in DMEM supplemented as above. RPE-1 retinal pigment epithelial cells 
were grown in DMEM and Ham F12 mix medium supplemented as above and buffered 
with sodium bicarbonate. HMV-II melanoma cell line, 22RV1 prostate carcinoma cells, 
NCI-H82 and NCI-H69 lung carcinoma cells, and NCI-N87 gastric cancer cell lines were 
grown in RPMI-1640 medium (Sigma-Aldrich) supplemented as above. Stably 
transfected U2OS cells were maintained in standard medium containing 1mg ml-1 G418 
(Invitrogen). siRNA duplexes were obtained from Life Sciences: Lamin A/C stealth 
RNAi: CCAUGAAGGAGGAACUGGACUUCCA and GCGUGAGGAGUUUAA-
GGAGCUGAAA, NAT10 stealth RNAi: GAGCAUGGACCUCUCUGAAUACAUA, 
and as control siRNA, stealth RNAi negative control duplexes were used.  Plasmid DNA 
and siRNA transfections were carried out using Lipofectamine 2000 and Lipofectamine 
RNAiMax (Life Sciences) respectively, following the manufacturer’s instructions. Cells 
were analysed 48 to 72 h after transfection. 
 
Drug treatments. The following KAT and KDAC inhibitors were included in the 
nuclear shape rescue screen, incubating cells with the molecules for 16 h: trichostatin A 
(1 µM), sodium butyrate (5 mM), tubacin (10 µM), SAHA (5 µM), curcumin (10 µM), 
garcinol (50 µM), anacardic acid (1 µM), MB-3 (5 µM), 4-(4-chlorophenyl)-2-(2-
cyclopentylidenehydrazinyl)thiazole (1) (50 µM), 4-(4-chlorophenyl)-2-(2-
cyclopentylidene-1-(prop-2-yn-1-yl)hydrazinyl)thiazole (2) (50 µM) and 
cyclopentylidene-[4-(4-cyanophenyl)thiazol-2-yl)hydrazine (4) (Remodelin) (10 to 50 
µM). For HGPS cellular fitness assays, Remodelin was incubated at 1 µM for 1 to 10 
days, renewing the medium every 3 days. For long-term senescence assay, cells were 
kept and passaged in medium containing 1 µM Remodelin or DMSO only for 12 
population doublings. Senescence was assessed after 8 days of Remodelin treatment 
when cells were at Population Doubling 12, and then after several weeks of Remodelin 
treatment, when cells reached Population Doubling 24 using the Senescence β-
Galactosidase Staining Kit #9860 from Cell Signaling. Nocodazole, colchicine and 
latrunculin A (Sigma-Aldrich) were used at 200ng/ml, 1 µg/ml and 1 µM respectively. 
Aphidicolin (Sigma-Aldrich) was used at 5 µg/ml for 16 h. Farnesyltransferase inhibitor 
FTI-277 was purchased from Tocris Bioscience and used at 5 µM. ATMi (KU55933) and 
ATRi (ATR-45) were obtained from Tocris Bioscience and from the Ohio State 
University respectively and used at 10 µM and 500 nM. Pifithrin alpha (Sigma-Aldrich) 
was used at 10 µM. 
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Live imaging of GFP-H2B cells. U2OS cells were transfected with siLMNA for 48h 
before addition of (1) at 50 µM. Pictures were acquired every 15 min for 16 h in z-stack 
of 0.2 µm interval with a Deltavision PersonalDV (Applied Precision, 512x512 
CoolSNAP HQ2 camera) equipped with a 100x UPlanSApo/1.40 oil objective (Olympus) 
and controlled with SoftWoRx software (Applied Precision). Movies were then 
assembled from pictures with ImageJ software.  
 
Flow cytometry. 10 µM EdU was incubated for 2 h when indicated. Cells were fixed in 
4% paraformaldehyde (Sigma-Aldrich). EdU was fluorescently labeled using the Click-
iT® EdU Flow Cytometry Assay Kit (Life Sciences). DNA was stained with 50 mg ml-1 
propidium iodide (Sigma-Aldrich) in phosphate buffer solution (PBS) containing 0.1% 
Triton X-100 and 0.5mg ml-1 DNase free RNase A (Sigma-Aldrich). Samples were 
processed on a FACSCalibur flow cytometer equipped with CellQuest software (Becton 
Dickinson). Results were analysed by FlowJo software (TreeStar).  
 
Nuclear circularity and nuclear area quantification. CellProfiler software was used to 
quantify nuclear circularity and nuclear area from DAPI staining pictures, using the 
“object size shape” measurement. The AreaShape measurement allowed the calculation 
of the Form Factor index (4 × π × Area/Perimeter2) corresponding to circularity (a Form 
Factor of 1 reflecting a perfect circle), as well as the calculation of nuclear Area.  
 
Proliferation assay. HGPS cells were plated at the same number in 24 well dishes. Next 
day, Remodelin (1 µM) or small molecule 1 (1 to 10 µM), were added to the wells and 
plates were transferred into an IncuCyte microscope (Essen BioScience). Phase contrast 
pictures were acquired every 2 h over 250 h. Percentage of cell confluence was calculated 
by the Cell Player integrated software (Essen BioScience) and analysed with GraphPad 
Prism® software.  
 
Protein purification from human cells. HEK293 cells were transiently transfected with 
NAT10 constructs and harvested after 48 h in PBS. Cells were lysed for 5 min at room 
temperature in IP lysis buffer (20 mM Tris pH 7.5, 40 mM NaCl, 2 mM MgCl2, 0.5% 
NP-40) freshly supplemented with 50 U/ml benzonase and EDTA-free protease inhibitor 
cocktail (Roche). After this initial lysis step, NaCl concentration was adjusted to 450 mM 
and samples were incubated at 4°C with rotation. Lysates were clarified by centrifugation 
(13,200 rpm, 20 min at 4°C), and after recovery NaCl concentration was equilibrated to 
150 mM. Lysates were used for immunoprecipitation reaction in IP buffer (25 mM Tris 
pH 7.5, 150 mM NaCl, 1.5 mM DTT, 10% glycerol, 0.5% NP-40) supplemented with 
protease inhibitors. Target proteins were captured with anti FLAG antibody (Sigma-
Aldrich) coupled to protein A/G-Dynabeads (Life Sciences). Complexes were washed 
with IP buffer containing incrementally increasing amounts of NaCl (250mM, 500mM, 
and 1M). Following this, the immuno-complexes were washed in TBS containing 
gradually decreasing amounts of NaCl (1M, 500mM, 250mM, and 150mM). At this 
point, elution was carried out using excess triple-Flag peptide (Sigma Aldrich). Eluted 
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proteins were loaded on a gel and the purification was verified by Silver Staining 
(SilverQuest kit, Life Sciences).   
 
Analysis of soluble or polymerised tubulin. U2OS cells pre-treated with 5 µM 
Remodelin for 16 h or with 10 µM nocodazole for 8h, were lysed in MT Stabilization 
Buffer (MSB) (85 mM PIPES [pH 6.9], 1 mM EGTA, 1 mM MgCl2, 2M glycerol, 0.5% 
Triton with 4 µg/ml Taxol). Lysates were kept at 4°C for 2 min and then centrifuged for 
10 min at 13,000 rpm. Supernatants, representing the soluble fraction of proteins, were 
transferred to new tubes, and Laemmli buffer was added. Pellets, representing the 
polymerized fraction of proteins, were washed once in MSB without Triton, and then 
resuspended in Laemmli buffer. Equal amounts of lysate were loaded on a gradient gel. 
 
Microtubules regrowth assay. 48 h after siRNA transfections, microtubules were 
depolymerized by cold treatment at 4°C for 1 h in cells pre-treated or not with 1 to 5 µM 
Remodelin for 16 h. Cold medium was replaced by pre-warmed medium and cells were 
incubated at 37°C for 5 or 15 min to allow microtubule nucleation and anchorage 
respectively.  Cells were fixed in PFA and stained with anti α-Tubulin antibody as 
described in the immunofluorescence procedure. 
 
Immunoblotting. Total cell extracts were prepared by scraping cells in SDS lysis buffer 
(4% SDS, 20% glycerol, and 120 mM Tris-HCl, pH 6.8), boiling for 5 min at 95°C, 
followed by 10 strokes through a 25-gauge needle. Before loading, lysates were diluted 
with a solution of 0.01% bromophenol blue and 200 mM DTT and boiled for 5 min at 
95°C. Proteins were resolved by SDS-PAGE on 4-12% gradient gels (NUPAGE, Life 
Sciences) and transferred onto nitrocellulose membrane (Protran; Whatman). Secondary 
antibodies conjugated to IRDye 800CW were from LI-COR Biosciences. Detection and 
quantification was performed with an imager (Odyssey; LI-COR Biosciences). 
 
Immunofluorescence. Cells were washed with PBS and fixed for 20 min with 2% PFA 
in PBS. Cells were permeabilised for 5 min with PBS/0.2% Triton X-100, and blocked 
with PBS/0.2% Tween 20 (PBS-T) containing 5% BSA. Coverslips were incubated for 1 
h with primary antibodies and for 30 min with appropriate secondary antibodies coupled 
to Alexa Fluor 488 or 594 fluorophores (Life Technologies), before being incubated with 
2µg/ml DAPI. Pictures were acquired with a FluoView 1000 confocal microscope 
(Olympus). For high resolution imaging, z-stacks were aquired with a Deltavision 
PersonalDV (Applied Precision, 1024x1024 CoolSNAP HQ2 camera, z-stack of 0.2 µm 
interval) or with a Deltavision OMX V3 in conventional mode (Applied Precision, 
512x512 Cascade II cameras (Photometrics), z-stack of 0.125 µm interval) both equipped 
with a 100x UPlanSApo/1.40 oil objective (Olympus) and controlled with SoftWoRx 
software (Applied Precision). Deconvolutions were then performed with SoftWoRx 
(Applied Precision) in conservative mode. The different channels were acquired 
sequentially. 
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Fluorescent labeling of clickable molecules. Cells were pre-incubated with clickable 
molecules 2 or 3 for 2 h before being fixed and permeabilised as described above. Click 
reaction was prepared using Invitrogen Click-iT reagents with Alexa fluor 488 Azide and 
incubated with fixed cells for 1 h in the dark. In case of co-labeling with another protein, 
the click reaction was performed before the antibody incubations.  
 
Antibodies. Antibodies used in this study are:  
Abcam antibodies:    Santa Cruz antibodies: 
Lamin A/C ab40567     Lamin A/C sc-6215 
HMG1 ab18256    p53 (DO-1) sc-126 
H2AX total ab11175    p21 sc-397 
Histone H3 ab1791 
β-actin ab8226    Cell Signaling antibodies:    
ATM (phospho S1981) ab81292  γH2AX 2577    
SUN1 ab124770    p-Rb (Ser 807/811) 9308    
anti-Giantin ab24586    Rb  9309     
α-tubulin T9026    p-p53 (Ser15) 9284 
H3K9me3 ab8898 
Sigma-Aldrich antibodies:   Others: 
α-tubulin FITC F2168   γH2AX 05-636 Millipore 
FLAG F3165     NAT10 13365-1-AP ProteinTech   
 
Micrococcal nuclease digestion sensitivity assay. 1x106 cells were trypsinized, 
harvested, and washed once with 1ml of 1xRSB buffer (10 mM Tris, pH 7.6, 15 mM 
NaCl, and 1.5 mM MgCl2). After centrifugation (3,00 x g), the cell pellet was 
resuspended in 1 ml of 1x RSB buffer with 1% Triton-X 100 and homogenized by five 
strokes with a loose-fitting glass pestle to release nuclei. Nuclei were collected by 
centrifugation (13, 000 x g) and washed twice with 1 ml of buffer A (15 mM Tris, pH 
7.5, 15 mM NaCl, 60 mM KCl, 0.34 M sucrose, 0.5 mM spermidine, 0.15 mM spermine, 
0.25 mM PMSF, and 0.1% b-mercaptoethanol). Nuclei were resuspended in Buffer A and 
aliquoted into 100 µl aliquots. 1.2µl of 0.1 M CaCl2 was added to each aliquot and nuclei 
were digested by addition of 0.25 µl of 200 U/ml MNase (Sigma-Aldrich) and incubated 
at 30°C. Each aliquot was put back on ice at different time points and digestion was 
immediately stopped by addition of 3µl EDTA. DNA was purified using the Qiagen PCR 
purification kit and 1500 ng of DNA was analysed on a 1.5% agarose gel. Digestion 
profiles were analysed using ImageJ and values were adjusted relative to the global 
intensity of each lane to compensate for DNA loading variations.  
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Lysine acetyltransferase (KAT) assay. The KAT assay was performed using the 
Fluorescent HAT Assay kit (Active Motif) using NAT10 purified from HEK293 cells and 
5 µg of purified MAP enriched Tubulin Porcine (Tebu-bio) as a substrate. Remodelin and 
clickable molecule 2 were used at 50 µM.  
 
Circular Dichroism Spectroscopy. CD experiments were performed using a Chirascan 
Circular Dichroism Spectrophotometer (Applied Photophysics, UK). 200 µl of purified 
FLAG-NAT10 at a final concentration of 10 µM in TBS + 0.1 % NP-40 (Sigma-Aldrich) 
was placed in a quartz cuvette with an optical path length of 1 mm, transferred to the 
spectrophotometer. CD scans were recorded at 25°C over the wavelength range of 180 to 
350 nm with a 1s response time, 1 nm pitch and 1.5-nm bandwidth. Compound 1 
solubilized in DMSO was added and the solution was incubated for 5 min before 
recording scans. CD spectra were buffer subtracted, zero corrected at 300 nm and 
normalized (Molar ellipticity θ is quoted in 105 deg cm2 dmol−1). 
 
DNA manipulations. All DNA constructs were validated to be mutation-free by DNA 
sequencing. A list of DNA oligonucleotides used in this study is provided below. pICE-
FLAG was generated by cloning annealed primers FLAG-S and FLAG-AS into HindIII- 
and BamHI-digested pICE, a new synthetic plasmid conferring puromycin-resistance to 
mammalian cells (29). To generate NAT10 cDNA resistant to NAT10 siRNA, NAT10 
cDNA was amplified from IMAGE clone 5166101 (Source Bioscience) using primer 
pairs NAT10-F and NAT10-siR-R, or NAT10-siR-F and NAT10-R. The resulting PCR 
products were fused together by PCR using primers NAT10-F and NAT10-R. The 
resulting PCR product was digested with BamHI and MluI and cloned into pICE-FLAG 
digested with the same restriction enzymes. To generate pICE-FLAG-NAT10-G641E, 
the G641E mutation was introduced into pICE-FLAG-NAT10 using QuickChange Site-
Directed Mutagenesis kit (Agilent Technologies), according to the manufacturer’s 
instructions and using primers NAT10-G641E-F and NAT10-G641E-R. 
 
List of DNA oligonucleotides used in this study. 
Name         Sequence 5’ to 3’ 
FLAG-S           AGCTTGCGGCCGCCGCCACCATGGATTACAAGGATGACGACGATAAGG 
FLAG-AS        GATCCCTTATCGTCGTCATCCTTGTAATCCATGGTGGCGGCGGCCGCA 
NAT10-F         GCCGGATCCATGCATCGGAAAAAGGTGGATAACCG 
NAT10-R         CGGACGCGTCTATTTCTTCCGCTTCAGTTTCATATC 
NAT10-siR-F  CTGAAATCAATGGATTTGAGTGAATATATTATCCGTGGGGACGATGAAGAGTGG 
NAT10-siR-R  GGATAATATATTCACTCAAATCCATTGATTTCAGCTTCCCTACTTCCTTCTTGTG 
NAT10-G641E-F  CAAGGGATGGGCTATGAGAGCCGTGCTCTGCAG 
NAT10-G641E-R  CTGCAGAGCACGGCTCTCATAGCCCATCCCTTG 
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Synthesis of Remodelin and derivatives. All solvents and reagents were purified using 
standard techniques or used as supplied from commercial sources (Sigma-Aldrich). NMR 
spectra were acquired on a Bruker 500 MHz instrument using deuterated solvents at 300 
K. Notation for the 1H NMR spectral splitting patterns includes: singlet (s), doublet (d), 
triplet (t), broad (br) and multiplet/overlapping peaks (m). Signals are quoted as 
  values in ppm and coupling constants (J) are quoted in Hertz. Mass spectra were 
recorded on a Micromass® Q-Tof (ESI) spectrometer. 
 
General procedure: The appropriate ketone or aldehyde was dissolved in isopropanol at 
a final concentration of 0.5 M and refluxed for 24h in the presence of an equimolar 
amount of thiosemicarbazide. The corresponding thiosemicarbazones were isolated by 
filtration and recrystallized from hot ethanol. Equimolar amounts of thiosemicarbazones 
and the desired haloketones were stirred at room temperature in isopropanol overnight at 
a final concentration of 0.2 M. The resulting products were recrystallized from hot 
ethanol several times to yield pure products and were used without further purification. 
 
4-(4-chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)thiazole hydrochloride salt (1) 
Thiosemicarbazide (20 g, 220 mmol) and cyclopentanone (19.43 ml, 220 mmol) were 
refluxed in 500 ml of isopropanol for 24 h. The precipitate was filtered and recrystallized 
from hot ethanol to provide the corresponding thiosemicarbazone (2-
cyclopentylidenehydrazine-1-carbothioamide) as pale yellow crystals. 2-
cyclopentylidenehydrazine-1-carbothioamide (10 g, 63 mmol) and 2,4’-
dichloroacetophenone (12 g, 63 mmol) were stirred overnight in 300 ml of 
isopropanol at room temperature. The precipitate was filtered and 
recrystallized from hot ethanol to yield the hydrochloride salt of the desired 
compound (16 g, 48 mmol, 77%) as light yellow needles. Spectral data were in 
agreement with those previously described in the literature (16). Molecule 1 
was resuspended in DMSO at 10mg/ml. 
 
4-(4-chlorophenyl)-2-(2-cyclopentylidene-1-(prop-2-yn-1-yl)hydrazinyl)thiazole (2) 
To a solution of 1 (1 g, 3 mmol) in freshly distilled DMF (75 ml) was added K2CO3 
(1.375 g, 10 mmol), triethylamine (1.4 ml, 10 mmol) and propargyl bromide 
(1.2 ml, 5 mmol, 80 wt. % in toluene). The solution turned purple after 12 h at 
room temperature. Propargyl bromide (1.2 ml) was added and the reaction 
mixture was stirred for another 12 h. The solvent was then evaporated under 
reduced pressure and the crude residue dissolved in CH2Cl2, washed several 
times with saturated solutions of NH4Cl and NaCl and dried over MgSO4. The 
solvent was evaporated under reduced pressure and the desired product (0.35 
g, 1 mmol, 34%) was obtained as a brown oil after regular column 
chromatography. TLC (Hexane : CH2Cl2, 80 : 20): Rf = 0.25; 1H NMR (500 
MHz, CDCl3): δ 7.78 (d, J = 8.0 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 6.86 (s, 
1H), 4.65 (s, 2H),  2.64–2.55 (m, 4H), 2.22 (s, 1H), 1.86–1.82 (m, 4H); 13C NMR (125 
MHz, CDCl3): δ 184.9, 171.8, 150,6, 133.4, 133.3, 128.6 (2C), 127.3 (2C), 105.2, 78.3, 
Cl
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72.5, 42.7, 33.8, 31.5, 24.9, 24.4; HRMS (m/z): [M]+ calcd. for C17H16ClN3S, 329.0758; 
found, 329.0747. Molecule 2 was resuspended in DMSO at 10mg/ml. 
 
1-Chloro-4-ethynilbenzene (Clickable inactive molecule 3) was purchased from Sigma-
Aldrich. 
 
4-(4-cyanophenyl)-2-(2-cyclopentylidenehydrazinyl)thiazole (4, Remodelin) 
2-cyclopentylidenehydrazine-1-carbothioamide (1 g, 4.46 mmol) and 2-bromo-
4’-cyanoacetophenone (700 mg, 4.45 mmol) were stirred overnight in 12 ml of 
isopropanol at room temperature. The precipitate was filtered and 
recrystallized from hot ethanol to yield the hydrobromide salt of the desired 
compound (559 mg, 1.98 mmol, 45%) as light yellow needles. 1H NMR (500 
MHz, CDCl3): δ 12.11 (br s), 7.84 (d, J = 9.0 Hz, 2H), 7.81 (d, J = 9.0 Hz, 2H), 
6.84 (s, 1H), 2.61 (t, J = 9.0 Hz, 2H), 2.51 (t, J = 9.0 Hz, 2H), 1.94–1.80 (m, 
4H); 13C NMR (125 MHz, CDCl3): δ 173.8, 169.5, 138.8, 133.5, 131.3, 126.3, 
118.0, 114.1, 103.8, 33.7, 31.2, 25.2, 25.0; HRMS (m/z): [M]+ calcd. for C15H15N4S, 
283.1009; found, 283.1017. Molecule 4 was resuspended in DMSO at 10mg/ml. 
 
Small molecules for protein pull-down assays. Biotinylated derivative 5 was 
synthesized from compounds 2, commercially available O-(2-aminoethyl)-O’-(2-
azidoethyl)heptaethylene glycol and (+)-biotin N-hydroxysuccinimide. Biotinylated 
derivatives 6 and control 7 were generated in situ from 2 and 3, by addition of PEG4 
carboxamide-6-azidohexanyl biotin (Life Sciences) and click reagents in cell extracts. 
 
 
 
 
 
 
 
 
 
 
 
Biotinylated small molecule pull-downs. Cells were harvested in PBS and lysed in 
RIPA buffer supplemented with 1 mM PMSF and protease inhibitors (Roche) for 30 min 
at 4°C with rotation. The supernatants were collected by centrifugation at 16,000 x g for 
10 min. Supernatants were then incubated with 40 µM of biotinylated small molecule or 
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for the competition experiment with 200 µM of (1) and 40 µM of biotinylated compound 
for 2 h. Streptavidin coated magnetic beads (Dynabeads M-280 Streptavidin, Life 
Sciences) were washed 3 times with binding buffer (25 mM Tris.HCl, 150 mM NaCl, 
0.1% Triton) and incubated with supernatants for 1 h at 4°C with rotation. The magnetic 
beads were washed 3 times with the binding buffer followed by boiling in Laemmli 
buffer for 5 min to elute the proteins. Samples were then loaded on 4-12% gradient gels 
(NUPAGE, Life Sciences), analyzed by silver staining (SilverQuest staining kit, Life 
Sciences) and specific bands were cut and analysed by LC-MS/MS. 
 
Clickable small molecule pull-downs. Cells were incubated with clickable compounds 2 
and control 3 for 2 h and cell lysates were prepared as described above. Small molecules 
were then coupled to biotin using the click reaction to form molecules 6 and 7. Click 
reaction reagents were added to the cell lysates as follows: 10 µM biotin azide (PEG4 
carboxamide-6-Azidohexanyl Biotin, Life Sciences), 10 mM sodium ascorbate (Sigma-
Aldrich), 2 mM CuSO4 (Life Sciences). Click reactions were incubated in the dark for 1 h 
at 4°C with rotation. Streptavidin beads were then incubated for 1 h and samples were 
eluted and loaded on a gel as described above, before immunoblotting. 
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Fig. S1: Small molecule 1 rescues nuclear shape defects and chromatin compaction 
of Lamin A/C depleted cells. A) and B) Nuclear shape visualization by DAPI staining of 
HeLa (A) or RPE-1 (B) cells depleted for Lamin A/C (siLMNA) and treated with various 
KAT inhibitors. Scale bars: 50 µm. C) Representative MNase digestion profile (left) in 
U2OS cells from three independent experiments and corresponding quantification (right). 
D) Quantification of nuclear area in U2OS cells (means of three independent experiments 
with n>198  s.d.). E) and F) Cell Profiler quantification of nuclear circularity of HeLa 
(E) or RPE-1 (F) cells from DAPI staining as shown in A) and B) (means of three 
independent experiments with n>252  s.d). G) Representative MNase digestion profile 
in U2OS cells (left) from three independent experiments and corresponding 
quantification of siLMNA cells (right). 
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Fig. S2: Small molecule 1 acts independently of the cell cycle and improves nuclear 
shape in cancer cells with low Lamin A/C expression. A) Nuclear shape rescue of 
LMNA depleted cells after treatment with 1 is independent of mitosis, and still occurs in 
cells synchronized in S phase by aphidicolin to prevent mitotic entry. Scale bars: 20 µm. 
B) and C) Cell cycle profiles of indicated cell lines analysed by flow cytometry. PI: 
propidium iodide. Scale bars: 20 µm. D) Analysis of Lamin A/C expression levels in 
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indicated cancer cell lines. Bottom panel: Image J quantification of Lamin A/C 
expression in cancer cells relative to normal RPE-1 cells. E) Representative pictures of 
DAPI staining showing nuclear shape improvement in low Lamin A/C expressing cancer 
cells after treatment with 1. Scale bars: 20 µm. 
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Fig. S3: Biotin analog of 1 retrieves the acetyl-transferase protein NAT10. A) 
Molecular structure of biotinylated analogue. B) Silver staining of proteins after pull-
down of biotinylated molecule and identification of specific bands (see arrows) 
decreasing in the presence of 5 equivalents of non-clickable molecule 1. The band 
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corresponding to NAT10 is magnified on the right (*) together with other specific and 
non-specific bands.  C) Specific protein hits retrieved by biotinylated small molecule and 
identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). 
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Fig. S4: Subcellular localization of the molecules and analysis of Remodelin binding 
to purified NAT10.  A) Fluorescent labeling of clickable control molecule 3 showing no 
specific staining, contrasting to molecule 2 (see Fig. 1K). Scale bar: 20 µm. B) NAT10 
depletion by siRNA (siNAT10) is observed by western blotting.  C) IF pictures of Lamin 
A/C and NAT10 staining within cells transfected or treated as indicated. Scale bar: 20 
µm. D) NAT10 was expressed and purified in human HEK293 cells and analysed by 
silver staining (left *). NAT10 folding was assessed by circular dichroism spectroscopy 
(right). In the absence of compound, the NAT10 spectra displayed a characteristic 
negative signal at 210 nm, reflecting the presence of a-helices. Upon addition of 
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molecule 1, absolute molar ellipticity increased, consistent with stabilization of NAT10 
by supramolecular stapling (30) and suggesting that stabilization of protein folding by 1 
might inhibit NAT10 activity. 
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Fig. S5: Screening of 1 analogs to identify structural requirements for nuclear shape 
rescue. A) Nuclear shape analysis by DAPI staining in siLMNA cells treated with the 
indicated analogs of 1. B) Dose-dependent nuclear shape rescue observed by DAPI 
staining of siLMNA cells, showing an ~5-fold increase in the potency of Remodelin 
compared to 1. Scale bar: 20 µm. 
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Fig. S6: NAT10 mutation G641E (MUT) does not affect its localization. A) 
Alignment of NAT10 GNAT (Gcn5-related N-acetyltransferase) domain showing the 
conservation of G641. B) Silver staining of purified FLAG-NAT10 WT or G641E mutant 
(MUT) from Human HEK293 cells. These proteins were used in acetyl-transferase 
activity assays (Fig. 2E). C) Characterization of U2OS cells stably expressing siRNA 
resistant constructs of FLAG-NAT10 WT and MUT. Expression of constructs and siRNA 
resistance was assessed by western blotting and D) the correct localization of both 
constructs was verified by IF staining using anti-NAT10 antibody or anti-FLAG antibody.  
Scale bars: 10 µm. 
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Fig. S7: Remodelin rescues nuclear shape of aged MRC5 cells but not Werner 
Syndrome cells in a dose-dependent manner. A) Misshapen nuclei observed by DAPI 
staining in MRC5 aged cells in culture, at population doubling 44 (PD44) was rescued by 
Remodelin. B) Quantification of misshapen nuclei after increasing concentrations of 
Remodelin (mean of three independent experiments ± s.e.m.). C) DAPI staining of non-
laminopathic Werner syndrome cells showing no nuclear shape improvement upon 
Remodelin treatment. D) Cell Profiler quantification of misshapen nuclei (means of three 
independent experiments ± s.d. n>273). Scale bars: 50 µm. 
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Fig. S8: Remodelin prevents FTI induced nuclear shape defects in non-progeric 
cells. A) Analysis of Lamin A/C processing after Remodelin or FTI treatment, showing 
that Remodelin is not a FTI. B) Representative pictures of Lamin A/C IF staining after 
the indicated treatments. Arrows indicate FTI induced misshapen nuclei in normal 
fibroblasts. Scale bar: 50 µm. C) Quantification of misshapen nuclei with the indicated 
cell lines and inhibitor treatments (means of three independent experiments ± s.e.m. 
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n>178). D) Representative pictures of DAPI staining showing effects of FTI and 
Remodelin on nuclear shape of U2OS cells. Scale bars: 20 µm. 
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Fig. S9: Remodelin improves global cellular fitness of HGPS cells. A) NAT10 
depletion in normal fibroblasts and HGPS AG11498 cells observed by western blotting, 
and showing that siNAT10 has no effect on Lamin A/C expression and processing. B) IF 
images showing nuclear shape improvement and decreased numbers of γH2AX foci in 
HGPS cells upon Remodelin treatment. Scale bars: 10 µm. C) Western Blotting analysis 
showing that Remodelin decreases γH2AX levels in both HGPS cell lines tested. D) 
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Western blotting analysis showing the effect of Remodelin on the p53 and DNA damage 
signalling pathways in HGPS AG11498 cells. E) Representative IF images of H3K9me3 
or SUN1 patterns quantified in F). Scale bars: 20 µm. G) IF staining showing more 
intense and homogenous DAPI staining, as well as reorganization of nucleolus 
architecture as observed by NAT10 staining upon Remodelin treatment. Scale bars: 10 
µm. H) Flow cytometry analysis after 2 hours of EdU incorporation in HGPS cells upon 
Remodelin treatment showing enhancement of DNA replication rate. I) Quantification of 
senescence-associated b-galactosidase positive cells after treatment with p53 inhibitor 
(Pifithrin) or with the indicated KAT inhibitors, showing that none of these compounds 
decrease the senescence in HGPS AG11498.  
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Fig. S10: Remodelin targets the microtubule network in HGPS cells to improve 
nuclear shape. A) Nuclear shape visualisation and quantification after treating cells with 
microtubule-disrupting agents. B) Microtubule regrowth assay in HGPS AG11498 cells 
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treated with Remodelin. α-tubulin inverted IF staining shows normal microtubule 
depolymerisation (T=0) and nucleation phase (T=5 min) but defects in the microtubule 
anchorage (T=15 min) upon Remodelin treatment. C) Microtubule regrowth assay as in 
B) showing defects in the microtubule anchorage (T=15 min) upon NAT10 depletion 
(siNAT10)  in the indicated HGPS cell lines and compared to cells transfected with 
control siRNA (siCT). Scale bars: 20 µm. 
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Fig. S11: Model of nuclear shape rescue by Remodelin. Laminopathic cells have 
enlarged, misshapen nuclei associated with disorganized chromatin structure. Upon 
Remodelin treatment, NAT10 acetyltransferase activity is inhibited, leading to disruption 
of microtubule anchorage at the centrosome and release of microtubule forces on the 
nuclear envelope. This release of mechanical stress on the nucleus contributes to nuclear 
shape rescue and global improvement of cell fitness and chromatin organization. 
Additional nuclear function of NAT10 might also contribute to chromatin reorganization, 
decreased DNA damage and decreased senescence. 
 
 
 
Movie S1: Live imaging of nuclear shape rescue in siLMNA cells. U2OS stably 
expressing GFP-H2B were transfected by siLMNA and treated with Remodelin. Pictures 
were acquired every 15 min over 12 h. 
 
 
